NeurologyLive® Friday 5 — March 17, 2023

Article

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending March 17, 2023.

Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Neuro News Roundup: Brain Awareness Week

For Brain Awareness Week — March 13, 2023, to March 19, 2023 —the team has culminated some of the biggest pieces of news to offer updates on new developments in literature in neurology to spread awareness on the prevention and treatment of neurological conditions.

Neuro News Roundup: Brain Awareness Week

2: NeurologyLive® Top Expert Interviews: National Sleep Awareness Week

In honor of National Sleep Awareness Week, a group of experts in the care of patients with sleep disorders—Wendy Troxel, PhD; Garth Whiteside; Milena Pavlova, MD; Ronald Gavidia, MD, MS; Renee Shellhaas, MD, MS, FAES—shared their perspectives on hot topics of treatment and management in sleep medicine.

NeurologyLive® Top Expert Interviews: National Sleep Awareness Week

3: NeuroVoices: Justin Sporrer, MD, on Improvements and Benefits to High Intensity Focused Ultrasound in Essential Tremor

In the latest edition of our in-depth Q&A series, the director of functional neurosurgery at Baptist Health Miami Neuroscience Institute provided perspective on the growth of high intensity focused ultrasound and the lessons learned when treating essential tremors.

NeuroVoices: Justin Sporrer, MD, on Improvements and Benefits to High Intensity Focused Ultrasound in Essential Tremor

4: Special Episode: Trofinetide Approved for Rett Syndrome

A special episode of Mind Moments® podcast features an exclusive interview with Jeffrey L. Neul, MD, PhD, the Annette Schaffer Eskind Chair and director of the Vanderbilt Kennedy Center, and professor of pediatrics at Vanderbilt University Medical Center, and the lead investigator on the phase 3 study of the drug, called LAVENDER (NCT04181723).

Special Episode: Trofinetide Approved for Rett Syndrome

5: Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DO

The vascular neurologist at Cleveland Clinic discussed the movitvations behind a study that assessed the extent HbA1c impacts the relationship between mechanical thrombectomy and poor outcomes. He shared some of the top-line findings the clinical community should be aware of and expressed why the small differences in glycemic control can make a major impact on the outcomes for patients with acute ischemic stroke. [WATCH TIME: 3 minutes]

Effect of HbA1c Elevation, Glycemic Control Following Mechanical Thrombectomy: David Baker, DO
Recent Videos
Clifford R. Jack Jr., MD
David T. Jones, MD
Clifford R. Jack Jr., MD
 Lisa Mosconi, PhD
Emma Ciafaloni, MD, an expert on Duchenne muscular dystrophy
 Justin Davanzo, MD
1 KOL is featured in this series.
Aliza Ben-Zacharia, PhD, DNP, ANP-BC, FAAN
© 2024 MJH Life Sciences

All rights reserved.